Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial
Open Access
- 1 February 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 26 (8) , 2521-2526
Abstract
Background. No prospective, randomized, double-blind trials of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers have previously been reported in adults or children with proteinuria secondary to Alport syndrome. Methods. This 12-week, double-blind multinational study investigated the effects of losartan 0.7–1.4 mg/kg/day compared with placebo (normotensive patients) or amlodipine 0.1–0.2 mg/kg/day up to 5 mg/day (hypertensive patients) on proteinuria [early morning-void urinary protein/creatinine ratio (UPr/Cr), baseline ≥34 mg/mmol] in 30 children of up to 17 years of age with Alport syndrome. Results. Twelve weeks of treatment with losartan significantly reduced proteinuria compared with placebo/amlodipine: losartan −14.7 mg/mmol (interquartile range −49.7 to −5.7 mg/mmol) or 31.6% reduction using a mixed model approach versus placebo/amlodipine 2.3 mg/mmol (−26.0 to 18.1 mg/mmol), P = 0.01 or 2.3% increase using a mixed model approach. Adverse event incidence was low and comparable between losartan and placebo/amlodipine groups. Conclusions. Losartan significantly lowered proteinuria and was well tolerated after 12 weeks of treatment in children aged 1–17 years with proteinuria secondary to Alport syndrome with or without hypertension, a population that has not previously been rigorously studied.Keywords
This publication has 18 references indexed in Scilit:
- Randomized, Double-Blind, Controlled Study of Losartan in Children with ProteinuriaClinical Journal of the American Society of Nephrology, 2010
- Treatment of Alport syndrome: beyond animal modelsKidney International, 2009
- Antihypertensive and antiproteinuric efficacy of ramiprilin children with chronic renal failureKidney International, 2004
- Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosisNephrology Dialysis Transplantation, 2004
- Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome11See Editorial by Abbate and Remuzzi, p. 764.Kidney International, 2003
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal InsufficiencyNew England Journal of Medicine, 1996
- In hereditary nephritis angiotensin-converting enzyme inhibition decreases proteinuria and may slow the rate of progressionAmerican Journal of Kidney Diseases, 1996
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993